Related Experiment Video
Updated: Jul 16, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus
Pierluigi Toniutto1, Carlo Fabris, Davide Bitetto
1University of Udine, Internal Medicine, Medical Liver Transplantation Unit, DPMSC, Piazzale SM della Misericordia 1, Udine 33100, Italy. pierluigi.toniutto@uniud.it
Abstract:
Idenix Pharmaceuticals Inc and Novartis AG are codeveloping valopicitabine dihydrochloride, a once-daily oral nucleoside for the potential treatment of HCV infection. In January 2005, a phase IIa clinical trial comparing valopicitabine dihydrochloride with pegylated IFN in treatment-naive HCV patients was ongoing, in addition to a phase IIb trial in patients that had previously failed pegylated IFN and ribavirin combination therapy. In January 2006, an international phase III trial in treatment-refractory patients was planned for the first half of the year, with a phase III trial in treatment-naive individuals planned for the second half of the year.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Hepatitis
Inhibitors of Virion Maturation and Assembly
Viral Hepatitis I: Introduction
